PL2853272T3 - Terapeutyczne zastosowanie przeciwciał anty-CS1 - Google Patents
Terapeutyczne zastosowanie przeciwciał anty-CS1Info
- Publication number
- PL2853272T3 PL2853272T3 PL14178061T PL14178061T PL2853272T3 PL 2853272 T3 PL2853272 T3 PL 2853272T3 PL 14178061 T PL14178061 T PL 14178061T PL 14178061 T PL14178061 T PL 14178061T PL 2853272 T3 PL2853272 T3 PL 2853272T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- antagonists
- subject
- present disclosure
- therapeutic use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70507—CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Luminescent Compositions (AREA)
- Glass Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46921103P | 2003-05-08 | 2003-05-08 | |
| US55762104P | 2004-03-29 | 2004-03-29 | |
| US55762004P | 2004-03-29 | 2004-03-29 | |
| US55762204P | 2004-03-29 | 2004-03-29 | |
| EP04760993A EP1624892B1 (en) | 2003-05-08 | 2004-05-10 | Therapeutic use of anti-cs1 antibodies |
| EP10183377.0A EP2371391B1 (en) | 2003-05-08 | 2004-05-10 | Therapeutic use of anti-CS1 antibodies |
| EP14178061.9A EP2853272B1 (en) | 2003-05-08 | 2004-05-10 | Therapeutic use of anti-CS1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2853272T3 true PL2853272T3 (pl) | 2018-01-31 |
Family
ID=33459144
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14178061T PL2853272T3 (pl) | 2003-05-08 | 2004-05-10 | Terapeutyczne zastosowanie przeciwciał anty-CS1 |
| PL04760993T PL1624892T3 (pl) | 2003-05-08 | 2004-05-10 | Terapeutyczne zastosowanie przeciwciał anty-CS1 |
| PL10183377T PL2371391T3 (pl) | 2003-05-08 | 2004-05-10 | Terapeutyczne zastosowanie przeciwciał anty-CS1 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04760993T PL1624892T3 (pl) | 2003-05-08 | 2004-05-10 | Terapeutyczne zastosowanie przeciwciał anty-CS1 |
| PL10183377T PL2371391T3 (pl) | 2003-05-08 | 2004-05-10 | Terapeutyczne zastosowanie przeciwciał anty-CS1 |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US20050025763A1 (https=) |
| EP (4) | EP2853272B1 (https=) |
| JP (4) | JP4887152B2 (https=) |
| KR (1) | KR101268707B1 (https=) |
| CN (1) | CN1805755B (https=) |
| AT (1) | ATE506076T1 (https=) |
| AU (2) | AU2004238363B2 (https=) |
| BE (1) | BE2016C056I2 (https=) |
| BR (1) | BRPI0410129B8 (https=) |
| CA (1) | CA2523001C (https=) |
| CY (4) | CY1111958T1 (https=) |
| DE (1) | DE602004032328D1 (https=) |
| DK (3) | DK2853272T3 (https=) |
| ES (2) | ES2643289T3 (https=) |
| FR (1) | FR16C1012I2 (https=) |
| HK (1) | HK1208815A1 (https=) |
| HU (2) | HUE034908T2 (https=) |
| LT (1) | LT2853272T (https=) |
| LU (1) | LU93274I2 (https=) |
| MX (1) | MXPA05012011A (https=) |
| NL (1) | NL300838I2 (https=) |
| PL (3) | PL2853272T3 (https=) |
| PT (3) | PT2853272T (https=) |
| SI (3) | SI2371391T1 (https=) |
| WO (1) | WO2004100898A2 (https=) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| NZ574979A (en) * | 2006-08-07 | 2012-06-29 | Abbott Biotherapeutics Corp | Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
| EP2069478A2 (en) * | 2006-08-07 | 2009-06-17 | PDL BioPharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| AU2007281684C1 (en) * | 2006-08-07 | 2013-12-19 | Abbvie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
| WO2009149021A2 (en) | 2008-06-02 | 2009-12-10 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides |
| EP2361263A1 (en) * | 2008-10-31 | 2011-08-31 | Abbott Biotherapeutics Corp. | Use of anti-cs1 antibodies for treatment of rare lymphomas |
| JP5818688B2 (ja) * | 2009-01-08 | 2015-11-18 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | 核酸増幅反応の効率を改善するための方法および組成物 |
| US20120269814A1 (en) * | 2009-11-10 | 2012-10-25 | Amgen Inc. | Anti-c mpl antibodies |
| PE20170687A1 (es) * | 2010-01-28 | 2017-06-13 | Glaxo Group Ltd | Proteinas de enlace a cd127 |
| TWI622402B (zh) | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| BR112013025415B1 (pt) | 2011-04-01 | 2021-03-16 | Immunogen, Inc | uso de um imunoconjugado antirreceptor de folato 1 (folr1) |
| US9200073B2 (en) | 2012-08-31 | 2015-12-01 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
| JP6374392B2 (ja) | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| HK1220470A1 (zh) * | 2013-03-15 | 2017-05-05 | Abbvie Biotechnology Ltd. | 抗cd25抗体及其用途 |
| US20140377253A1 (en) * | 2013-03-15 | 2014-12-25 | Abbvie Biotherapeutics Inc. | Fc variants |
| CN105377897A (zh) * | 2013-05-03 | 2016-03-02 | 俄亥俄州创新基金会 | Cs1-特异性嵌合抗原受体工程化的免疫效应细胞 |
| EP3024482A4 (en) * | 2013-07-24 | 2017-03-15 | The General Hospital Corporation | Methods for diagnosing and treating immune disease |
| CN113150145B (zh) | 2013-08-30 | 2025-02-14 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
| US9482289B2 (en) | 2013-10-14 | 2016-11-01 | Club Car, Llc | Self-preloading shift lever |
| ES2707057T3 (es) | 2013-11-06 | 2019-04-02 | Bristol Myers Squibb Co | Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple |
| WO2015069703A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| US20170051037A1 (en) * | 2014-05-02 | 2017-02-23 | Cellectis | Cs1 specific multi-chain chimeric antigen receptor |
| SI3157561T1 (sl) * | 2014-06-17 | 2020-08-31 | Medlmmune Limited | Izboljšana protitelesa alfa-V beta-8 |
| KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
| US10752902B2 (en) * | 2014-09-23 | 2020-08-25 | Board Of Trustees Of Michigan State University | Compositions comprising fusion proteins useful for modulating an immune response |
| AU2015339012B2 (en) | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
| EP3227335A1 (en) | 2014-12-04 | 2017-10-11 | Bristol-Myers Squibb Company | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
| DE102015102183B4 (de) * | 2015-02-16 | 2018-03-01 | Robert Bosch Automotive Steering Gmbh | Lenkzwischenwelle für ein Kraftfahrzeug und Verfahren zum Betreiben einer Lenkzwischenwelle für ein Kraftfahrzeug |
| WO2016134371A2 (en) | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| WO2016168769A1 (en) * | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Chimeric receptor t cell switches for her2 |
| RS62352B1 (sr) | 2015-06-29 | 2021-10-29 | Bristol Myers Squibb Co | Imunoterapijski režimi doziranja koji obuhvataju pomalidomid i anti-cs1 antitelo za lečenje kancera |
| HK1255161A1 (zh) | 2015-07-15 | 2019-08-09 | Juno Therapeutics, Inc. | 用於过继性细胞治疗的工程细胞 |
| CN116440279B (zh) | 2015-09-17 | 2026-02-24 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| NZ756975A (en) * | 2017-03-13 | 2022-12-23 | Intrinsic Lifesciences Llc | Antibodies to human erythroferrone and uses thereof |
| US11124579B2 (en) | 2017-03-29 | 2021-09-21 | Agency For Science, Technology And Research | Anti oligosaccharide antibody |
| BR112019027133B8 (pt) | 2017-06-20 | 2022-08-09 | Inst Curie | Uso de uma célula imune modificada deficiente para suv39h1 |
| KR20230008269A (ko) * | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| EP3704229B1 (en) | 2017-11-01 | 2023-12-20 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
| US12258580B2 (en) | 2017-11-01 | 2025-03-25 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| PT3703750T (pt) | 2017-11-01 | 2025-01-17 | Memorial Sloan Kettering Cancer Center | Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes |
| SG11202003501XA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| CN119193493A (zh) | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| MX2020005907A (es) | 2017-12-08 | 2020-10-19 | Juno Therapeutics Inc | Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma. |
| US12161670B2 (en) | 2017-12-08 | 2024-12-10 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CA3093200A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Anti-phf-tau antibodies and uses thereof |
| EP3814369A1 (en) | 2018-06-29 | 2021-05-05 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Tweak-receptor agonists for use in combination with immunotherapy of a cancer |
| CN112805378A (zh) | 2018-08-09 | 2021-05-14 | 朱诺治疗学股份有限公司 | 用于评估整合核酸的方法 |
| CN109406798A (zh) * | 2018-10-29 | 2019-03-01 | 美康生物科技股份有限公司 | 肌酐酶法检测试剂盒 |
| MA54078A (fr) | 2018-11-01 | 2021-09-15 | Juno Therapeutics Inc | Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| EP3873937A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| IL263394A (en) * | 2018-11-29 | 2020-05-31 | Amit Ido | Methods of activating dysfunctional immune cells and treatment of cancer |
| WO2020223535A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| CA3136742A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| BR112022001148A2 (pt) | 2019-07-23 | 2022-03-15 | Inst Nat Sante Rech Med | Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto |
| US20220390455A1 (en) | 2019-11-05 | 2022-12-08 | Bristol-Myers Squibb Company | M-protein assays and uses thereof |
| MX2022009584A (es) * | 2020-02-05 | 2022-10-07 | Navaux Inc | Anticuerpos anti-hepsina y usos de los mismos. |
| JP2023522857A (ja) | 2020-04-10 | 2023-06-01 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用 |
| KR20230024283A (ko) | 2020-05-13 | 2023-02-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도 |
| JP2023531531A (ja) | 2020-06-26 | 2023-07-24 | ジュノ セラピューティクス ゲーエムベーハー | 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法 |
| EP4188395A1 (en) | 2020-07-30 | 2023-06-07 | Institut Curie | Immune cells defective for socs1 |
| CN114286691B (zh) * | 2020-08-06 | 2024-08-06 | 武汉思安医疗技术有限公司 | Cs1-抗体和抗cs1-car-t细胞 |
| EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
| CN117693508A (zh) | 2021-03-03 | 2024-03-12 | 朱诺治疗学股份有限公司 | T细胞疗法和dgk抑制剂的组合 |
| JP2024517863A (ja) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
| EP4337763A1 (en) | 2021-05-10 | 2024-03-20 | Institut Curie | Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases |
| US20250304915A1 (en) | 2021-05-25 | 2025-10-02 | Institut Curie | Myeloid Cells Overexpressing BCL2 |
| JP2025501272A (ja) | 2021-12-28 | 2025-01-17 | ムネモ・セラピューティクス | 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞 |
| KR20240137075A (ko) | 2022-01-28 | 2024-09-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 조성물의 제조 방법 |
| AU2023221861A1 (en) | 2022-02-18 | 2024-09-05 | Rakuten Medical, Inc. | Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use |
| EP4499677A1 (en) | 2022-03-31 | 2025-02-05 | Institut Curie | Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| EP4532695A1 (en) | 2022-05-25 | 2025-04-09 | Celgene Corporation | Methods of manufacturing t cell therapies |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| CN115141825A (zh) * | 2022-08-12 | 2022-10-04 | 武汉希望组生物科技有限公司 | 一种微小型昆虫基因组dna的提取方法 |
| EP4583876A1 (en) | 2022-09-08 | 2025-07-16 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| CN120344563A (zh) * | 2022-12-02 | 2025-07-18 | 广州荔泰生物科技有限公司 | 人cs1 car-t细胞 |
| WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
| JP2026504491A (ja) | 2023-02-03 | 2026-02-05 | ツェー３エス２ ゲーエムベーハー | 操作された免疫細胞の非ウイルス的製造のための方法 |
| WO2026006370A1 (en) | 2024-06-28 | 2026-01-02 | Immunitybio, Inc. | Anti-slamf7 antibodies and therapeutics |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5004692A (en) | 1987-12-15 | 1991-04-02 | Protein Design Labs, Inc. | Cloning and expression of phosopholipase C genes |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| KR0162259B1 (ko) | 1989-12-05 | 1998-12-01 | 아미 펙터 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
| US20020099179A1 (en) * | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
| JPH07101999A (ja) * | 1993-10-06 | 1995-04-18 | Hagiwara Yoshihide | 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列 |
| US5637684A (en) | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
| US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| AU6094696A (en) | 1995-06-05 | 1996-12-24 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefor |
| US6607898B1 (en) * | 1996-03-26 | 2003-08-19 | Oncomedx, Inc. | Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum |
| JP2001522239A (ja) | 1997-03-21 | 2001-11-13 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | ８７個のヒト分泌タンパク質 |
| CA2328895A1 (en) | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2000011150A1 (en) | 1998-08-25 | 2000-03-02 | Incyte Pharmaceuticals, Inc. | Cell surface immunomodulators |
| US20030009013A1 (en) * | 1998-12-30 | 2003-01-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU2757500A (en) | 1999-02-10 | 2000-08-29 | Human Genome Sciences, Inc. | 33 human secreted proteins |
| CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| WO2000055627A1 (en) | 1999-03-15 | 2000-09-21 | Eos Biotechnology, Inc. | Reusable low fluorescent plastic biochip |
| JP2004522402A (ja) | 1999-06-02 | 2004-07-29 | ジェネンテック・インコーポレーテッド | 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸 |
| CA2380355A1 (en) | 1999-09-01 | 2001-03-08 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU2911601A (en) * | 1999-12-23 | 2001-07-03 | Bristol-Myers Squibb Company | Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof |
| AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20040038339A1 (en) * | 2000-03-24 | 2004-02-26 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| HK1054316A1 (zh) | 2000-05-26 | 2003-11-28 | Smithkline Beecham Corporation | 用於治疗rank配体介导疾病的抗-rank配体单克隆抗体 |
| US6410271B1 (en) | 2000-06-23 | 2002-06-25 | Genetastix Corporation | Generation of highly diverse library of expression vectors via homologous recombination in yeast |
| NZ527283A (en) * | 2001-01-29 | 2006-03-31 | Biogen Idec Inc | Modified antibodies and methods of use |
| EP1379264A4 (en) | 2001-03-21 | 2009-07-08 | Human Genome Sciences Inc | HUMAN SECRETED PROTEINS |
| US20030099974A1 (en) * | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| WO2003018621A2 (en) | 2001-08-23 | 2003-03-06 | Oxford Biomedica (Uk) Limited | Genes |
| US20040038877A1 (en) | 2001-10-02 | 2004-02-26 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US6478825B1 (en) * | 2001-11-28 | 2002-11-12 | Osteotech, Inc. | Implant, method of making same and use of the implant for the treatment of bone defects |
| US7041499B2 (en) * | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| EP2361263A1 (en) | 2008-10-31 | 2011-08-31 | Abbott Biotherapeutics Corp. | Use of anti-cs1 antibodies for treatment of rare lymphomas |
| CN104010774B (zh) | 2011-09-15 | 2017-10-13 | 康富真信息技术股份有限公司 | 用于自动生成机器人程序的系统和方法 |
| ES2741897T3 (es) | 2012-02-13 | 2020-02-12 | Radius Eng Inc | Cartucho reutilizable para moldeo por inyección |
-
2004
- 2004-05-07 US US10/842,011 patent/US20050025763A1/en not_active Abandoned
- 2004-05-10 DK DK14178061.9T patent/DK2853272T3/da active
- 2004-05-10 DK DK04760993.8T patent/DK1624892T3/da active
- 2004-05-10 PL PL14178061T patent/PL2853272T3/pl unknown
- 2004-05-10 SI SI200432193T patent/SI2371391T1/sl unknown
- 2004-05-10 WO PCT/US2004/014866 patent/WO2004100898A2/en not_active Ceased
- 2004-05-10 HU HUE14178061A patent/HUE034908T2/hu unknown
- 2004-05-10 EP EP14178061.9A patent/EP2853272B1/en not_active Expired - Lifetime
- 2004-05-10 ES ES14178061.9T patent/ES2643289T3/es not_active Expired - Lifetime
- 2004-05-10 EP EP10183377.0A patent/EP2371391B1/en not_active Expired - Lifetime
- 2004-05-10 SI SI200431707T patent/SI1624892T1/sl unknown
- 2004-05-10 PT PT141780619T patent/PT2853272T/pt unknown
- 2004-05-10 BR BRPI0410129A patent/BRPI0410129B8/pt not_active IP Right Cessation
- 2004-05-10 PT PT04760993T patent/PT1624892E/pt unknown
- 2004-05-10 CN CN2004800164542A patent/CN1805755B/zh not_active Expired - Lifetime
- 2004-05-10 DK DK10183377.0T patent/DK2371391T3/da active
- 2004-05-10 JP JP2006532992A patent/JP4887152B2/ja not_active Expired - Lifetime
- 2004-05-10 DE DE602004032328T patent/DE602004032328D1/de not_active Expired - Lifetime
- 2004-05-10 SI SI200432408T patent/SI2853272T1/sl unknown
- 2004-05-10 PL PL04760993T patent/PL1624892T3/pl unknown
- 2004-05-10 AT AT04760993T patent/ATE506076T1/de active
- 2004-05-10 CA CA2523001A patent/CA2523001C/en not_active Expired - Lifetime
- 2004-05-10 EP EP04760993A patent/EP1624892B1/en not_active Expired - Lifetime
- 2004-05-10 PL PL10183377T patent/PL2371391T3/pl unknown
- 2004-05-10 ES ES10183377.0T patent/ES2516840T3/es not_active Expired - Lifetime
- 2004-05-10 PT PT101833770T patent/PT2371391E/pt unknown
- 2004-05-10 LT LTEP14178061.9T patent/LT2853272T/lt unknown
- 2004-05-10 MX MXPA05012011A patent/MXPA05012011A/es active IP Right Grant
- 2004-05-10 EP EP17176948.2A patent/EP3275463A1/en not_active Withdrawn
- 2004-05-10 AU AU2004238363A patent/AU2004238363B2/en not_active Expired
-
2005
- 2005-11-07 KR KR1020057021141A patent/KR101268707B1/ko not_active Expired - Lifetime
-
2009
- 2009-03-10 US US12/401,531 patent/US20090238827A1/en not_active Abandoned
- 2009-03-10 US US12/401,513 patent/US8133981B2/en not_active Expired - Lifetime
- 2009-11-02 US US12/610,899 patent/US8008450B2/en not_active Expired - Lifetime
-
2010
- 2010-08-25 AU AU2010214661A patent/AU2010214661B2/en not_active Expired
-
2011
- 2011-06-30 US US13/174,134 patent/US8445646B2/en not_active Expired - Fee Related
- 2011-07-14 CY CY20111100687T patent/CY1111958T1/el unknown
- 2011-09-22 JP JP2011207654A patent/JP5976288B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-15 US US13/894,857 patent/US9175081B2/en not_active Expired - Lifetime
-
2014
- 2014-02-20 JP JP2014030549A patent/JP6042834B2/ja not_active Expired - Lifetime
- 2014-10-23 CY CY20141100872T patent/CY1115671T1/el unknown
-
2015
- 2015-09-22 US US14/860,906 patent/US10442859B2/en not_active Expired - Lifetime
- 2015-09-29 HK HK15109572.0A patent/HK1208815A1/en unknown
-
2016
- 2016-07-20 JP JP2016142300A patent/JP2017019795A/ja active Pending
- 2016-10-20 HU HUS1600042C patent/HUS1600042I1/hu unknown
- 2016-10-24 LU LU93274C patent/LU93274I2/fr unknown
- 2016-10-24 BE BE2016C056C patent/BE2016C056I2/fr unknown
- 2016-10-25 NL NL300838C patent/NL300838I2/nl unknown
- 2016-10-26 CY CY2016035C patent/CY2016035I2/el unknown
- 2016-10-27 FR FR16C1012C patent/FR16C1012I2/fr active Active
-
2017
- 2017-09-15 CY CY20171100980T patent/CY1119353T1/el unknown
-
2019
- 2019-10-10 US US16/599,035 patent/US20200031929A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1600042I1 (hu) | Anti-CS1 antitestek terápiás alkalmazása | |
| IL178121A0 (en) | Therapeutic use of anti-cs1 antibodies | |
| WO2005044854A3 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| WO2004004633A3 (en) | Use of tnfalpha antibodies and another drug | |
| EA200100822A1 (ru) | Baff, относящиеся к нему блокирующие агенты и их применение в стимуляции и ингибировании b-клеток и иммуноглобулинов в иммунных реакциях | |
| BRPI0413489A (pt) | composições polipeptìdicas de ligação a cd20 | |
| MXPA06003788A (es) | Anticuerpos completamente humanos contra 4-1bb humano (cd137). | |
| PT942740E (pt) | Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf | |
| EA200600921A1 (ru) | Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний | |
| DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
| WO2002092016A3 (en) | Therapeutic use of rank antagonists | |
| CY1115003T1 (el) | Θεραπευτικη χρηση των αντισωματων αντι-cs1 | |
| PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
| WO2003097082A3 (en) | Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies | |
| WO2004081046A3 (en) | Human monoclonal antibodies against apociii and their use in the therapy of atherosclerosis | |
| WO2004053064A3 (en) | Engineered fab'fragment anti-tumor necrosis factor alpha in combination with disease modifying anti-rheumatic drugs | |
| DE50210279D1 (de) | Screeningverfahren mit bnpi und dnpi | |
| WO2001090361A3 (en) | Modulation of inflammation by protease-treated mcp-3 chemokine |